Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. develops antibody-based medicines for autoimmune and rare diseases, with a central focus on thyroid eye disease. Its TED portfolio includes veligrotug, an intravenously administered humanized monoclonal antibody targeting IGF-1R, and elegrobart, a subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R.
Recurring company news covers clinical results from the THRIVE and REVEAL programs, regulatory updates for biologics applications, commercial preparation for TED therapies, and progress across earlier pipeline work, including anti-TSHR and FcRn inhibitor programs. Viridian also reports financial results, public equity and convertible-note financings, royalty-related funding updates, and Nasdaq inducement equity grants tied to employee compensation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Viridian Therapeutics (NASDAQ: VRDN) announced key updates on its thyroid eye disease (TED) program at the ARVO 2023 meeting in New Orleans, running from April 23-27, 2023. A significant aspect includes the oral presentation of Phase 1/2 trial results for its lead candidate VRDN-001, which demonstrated proof-of-concept with notable reductions in proptosis and improved clinical activity scores. Additionally, new preclinical data for VRDN-002 and VRDN-003 will be shared via poster presentations, focusing on pharmacokinetics and safety. The company is progressing VRDN-001 through its Phase 3 THRIVE trial and plans to initiate THRIVE-2 for chronic TED, showcasing a commitment to advancing innovative treatments for this debilitating condition, which affects over 250,000 individuals in the U.S. and Europe.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced the appointment of Tony Casciano as Chief Commercial Officer (CCO) and the departure of Carrie Melvin from her role as Chief Operating Officer (COO). Casciano brings over 20 years of experience in biopharma, including leadership roles at Teal Bio and AMAG Pharmaceuticals. Under his leadership, Viridian aims to strengthen its commercial operation, particularly with its lead asset, VRDN-001, currently in a Phase 3 trial for thyroid eye disease (TED). The company is also pursuing additional therapies for TED. The management transition is seen as a critical step in the company’s growth, as it seeks to deliver novel therapies to underserved populations.